Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H23N.CH4O3S |
Molecular Weight | 265.413 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC1(C)CC(C)(C)CC(C)(N)C1
InChI
InChIKey=CLUKHUGGXSIGRX-UHFFFAOYSA-N
InChI=1S/C11H23N.CH4O3S/c1-9(2)6-10(3,4)8-11(5,12)7-9;1-5(2,3)4/h6-8,12H2,1-5H3;1H3,(H,2,3,4)
Molecular Formula | C11H23N |
Molecular Weight | 169.307 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane (MRZ 2/579), an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain. Similar to memantine, neramexane is an NMDA receptor channel blocker with moderate affinity. It displays voltage dependency, and rapid unblocking kinetics. Neramexane also has been shown to block acetylcholine-evoked responses by antagonizing the alpha-9 alpha-10 nicotinic acetylcholine receptor. Neramexane has a novel mechanism of action and is expected to improve the patients' psychological suffering and difficulties in their life associated with tinnitus by its properties to inhibit the abnormal activity and electric potential of nerve in the inner ear, nerve and cerebral cortex. Neramexane is expected to improve the patients' psychological suffering and difficulties in their life associated with tinnitus by inhibiting the excessive excitation in the auditory pathway from the inner ear to nerve and cerebral cortex via mainly its two pharmacological properties. 1) Neramexane inhibits the excessive nerve excitation in the auditory pathway between the inner ear and cerebral cortex via NMDA antagonistic activity. 2) Neramexane inhibits the nerve excitation in the inner ear via nicotinic acetylcholine receptor antagonistic activity. A phase III trial is currently under investigation for tinnitus.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. | 1999 Jan |
|
Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? | 2004 Apr |
|
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. | 2005 Jun |
|
Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine in neuropathic rats. | 2005 Sep 5 |
|
Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. | 2007 Jul 2 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00405886
Tinnitus: Neramexane 25 -75 mg/d, oral tablets, duration: 16 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10494883
Neramexane (MRZ 2/579) blocked steady-state inward current responses of cultured hippocampal neurones to NMDA with an IC50 of 1.11 uM at -70 mV. Much higher concentrations of MRZ 2/579 blocked voltage-activated Ca2+ channels with an IC50 of 340 uM. MRZ 2/579 (10 uM) reduced peak inward current responses of neuronal nicotinic receptors only to 72.3% of control. MRZ 2/579 (10-100 uM) had little or no effect at AMPA and GABA(A) receptors.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:59:09 UTC 2023
by
admin
on
Fri Dec 15 15:59:09 UTC 2023
|
Record UNII |
9M85GXG84D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000126341
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
9M85GXG84D
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
SUB32871
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
C75163
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
11425584
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
457068-92-7
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
DTXSID10196605
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
CHEMBL2110954
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY | |||
|
PP-37
Created by
admin on Fri Dec 15 15:59:09 UTC 2023 , Edited by admin on Fri Dec 15 15:59:09 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |